

12-17-99

A/Reissue

12/16/99
1c135 U.S. PTO

jc525 U.S. PTO
09/465444
12/16/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX REISSUE

Assistant Commissioner of Patents
Washington, D.C. 20231

REISSUE APPLICATION TRANSMITTAL

Transmitted herewith is the application for reissue of U.S.

☒ Utility Patent ☐ Plant Patent ☐ Design Patent

No.: US 5,698,197 issued on December 16, 1997

Inventor(s): Founds et al.

Title: MONOCLONAL ANTIBODY SPECIFIC FOR ADVANCED
GLYCOSYLATION ENDPRODUCTS IN BIOLOGICAL SAMPLES

Enclosed are the following:

- I. Specification and claim(s) (37 C.F.R. § 1.173)
- A. ☒ 22 page(s) of specification (including title page)
☒ 2 page(s) of claims
☒ 1 page(s) of abstract
☒ 7 page(s) of drawings

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this Reissue Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EL 093 228 402 US, addressed to the: BOX REISSUE, Assistant Commissioner for Patents, Washington, D.C. 20231, on December 16, 1999.


Suzanne M. Zalot

II. Declaration and power of attorney

☒ 3 pages of declaration and power of attorney (executed).

III. Preliminary amendment

☐ Attached

IV. Offer to surrender the original letters patent in accordance with 37 C.F.R. § 1.178 is enclosed along with:

- ☒ consent of assignee.
- ☒ copy of assignment enclosed
- ☒ Offer to surrender is by the assignee of the entire interest attached.
- ☒ A certificate under 37 CFR 3.73(b) is attached

V. Letters patent

- ☐ Original letters patent are attached.
- ☐ Declaration that original letters patent lost or inaccessible is attached.
- ☒ A copy of the original printed patent is attached.

VI. Petition to proceed without assignee's assent.

☐ Attached hereto is a "PETITION TO PROCEED WITH REISSUE APPLICATION WITHOUT ASSIGNEE'S ASSENT".

VII. Information Disclosure Statement

- ☐ Attached
- ☐ Copies of the IDS citation(s) is/are attached.

VIII. ☒ Applicant Claims the priority of US Application Serial No. 08/367,507 filed December 30, 1994 entitled A MONOCLONAL ANTIBODY SPECIFIC FOR ADVANCED GLYCOSYLATION ENDPRODUCTS IN BIOLOGICAL SAMPLES.

IX. Priority-35 U.S.C. § 119 (foreign priority)

- ☐ Priority of application Application No. _____, filed on, in _____
_____ is claimed under 35 U.S.C. § 119.
- ☐ The certified copy has been filed in prior application Application No. 0 /
_____, filed on _____.

X. Basic Filing Fee Calculation (37 C.F.R. § 1.16(h), (i) and (j))

The reissue application presents, for fee calculation purposes, 23 total claims; 3 independent claims and 2 multiple-dependent claims that account for 9 claims.

The basic filing fee under 37 CFR 1.16(h) is \$760.00
3 Additional Claims @ \$18.00 = \$54.00
Total Fee Enclosed \$814.00

XI. Small Entity Status (*if applicable*)

- ☐ A statement that this filing is by a small entity is
- ☐ attached.
- ☐ will be forwarded.

XII. Additional Fee Payments

- ☐ Payment is being made for "PETITION TO PROCEED WITH REISSUE
APPLICATION WITHOUT ASSIGNEE"
(37 C.F.R. § 1.17(h)).....\$130.00

XIII. Authorization To Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees not included in the payment made herewith, but required to obtain a filing date to Deposit Account No. 04-0480.

XIV. This reissue application is being filed because the patentee claimed less than the patentee had a right to claim. As a result, this reissue application contains claims that are broader than the claims of US Patent No. 5,698,197. This reissue application is timely filed within two years of the issuance of US Patent No. 5,698,197 on 16 December 1997.